These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24687880)

  • 1. [What is the optimal dose for the prophylactic treatment of chronic migraine patients?].
    Irimia P; Esteve-Belloch P; Murie-Fernandez M; Martinez-Vila E
    Rev Neurol; 2014 Mar; 58 Suppl 2():S13-9. PubMed ID: 24687880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
    Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
    Green MW; Rothrock JF
    Toxicon; 2018 Jun; 147():116-119. PubMed ID: 29596847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation.
    Cheng F; Ahmed F
    Expert Opin Drug Saf; 2021 Nov; 20(11):1275-1289. PubMed ID: 34187265
    [No Abstract]   [Full Text] [Related]  

  • 11. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
    Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
    J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE; Silberstein S
    Drugs; 2018 Apr; 78(5):589-600. PubMed ID: 29532439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Onabotulinumtoxin A in the treatment of chronic migraine].
    Láinez-Andrés JM
    Rev Neurol; 2012 Apr; 54 Suppl 2():S39-50. PubMed ID: 22532242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [OnabotulinumtoxinA in chronic migraine: from the theory of clinical trials to clinical practice].
    Leira R
    Rev Neurol; 2014 Mar; 58 Suppl 2():S3-11. PubMed ID: 24687883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
    J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
    Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.